Insmed

Insmed: Leerink Partners maintains Outperform, PT raised to $215 from $210.

Insmed's Arikayce Meets Goal in Label Expansion Study, Shares Rise 6%

Insmed shares surge 5.87% intraday after positive ENCORE trial data supports Arikayce label expansion in MAC lung disease.

Insmed: Stifel Raises PT to $208 from $205, Maintains Buy Rating

Wells Fargo Maintains Overweight on Insmed, Raises PT to $177 from $175

Catalyst<ul> <li>Most analysts rate INSM Buy or Strong Buy, showing broad institutional optimism.</li> <li>Large and Extra-large fund flows show positive inflow trends, indicating institutional confidence.</li> <li>The company shows positive fundamental factors including strong days sales outstanding and interest coverage ratio, suggesting improved debt servicing ability and liquidity management.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Recent MACD Golden Cross signal suggests a biased bearish outlook.</li> <li>Market expectations for INSM remain pessimistic with rating inconsistencies among analysts.</li></ul>

Key Factors

Insmed (INSM) announced positive top-line Phase III ENCORE study results for ARIKAYCE in newly diagnosed MAC lung disease patients, meeting the primary endpoint.The ENCORE trial demonstrated a 3.11-point improvement in respiratory symptoms and an 87.8% culture conversion rate for ARIKAYCE at six months.Insmed's stock surged 6.33% intraday following the ENCORE study results, with plans to submit data to the FDA and Japan's PMDA for label expansion.Insmed's Brinsupri (brensocatib) received FDA approval in August 2025 as the first treatment for non-cystic fibrosis bronchiectasis and showed Phase 3 ASPEN data reducing pulmonary exacerbations.Insmed shares rose over 10% after positive Phase 3b study results for ARIKAYCE, with plans to file a supplemental new drug application with the FDA in H2 2026.

INSM News